Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
复制标题
DOI：
10.3390/pharmaceutics13040525
复制
发表时间：
2021-04-09
期刊：
影响因子：
5.4
通讯作者：
Kim DH
中科院分区：
文献类型：
--
作者：
Kim KS;Kim DH;Kim DH
在各种免疫疗法中，使用NK细胞过继转移的自然杀伤（NK）细胞癌症免疫疗法通过靶向逃避宿主免疫监视的肿瘤细胞而占据独特的地位。作为一线先天效应细胞，已经揭示NK细胞具有直接消除癌细胞和放大抗癌免疫系统的独特机制。在过去的40年里，NK细胞癌症免疫疗法在临床前和临床环境中显示出令人鼓舞的报告。2021年，共有288项临床试验正在研究各种NK细胞免疫疗法治疗血液和实体恶性肿瘤。然而，临床结果并不令人满意，仍然存在挑战。主要的局限性归因于免疫抑制性肿瘤微环境（TME）、NK细胞的低活性、NK细胞的不充分归巢以及NK细胞与肿瘤细胞的接触频率有限。促进NK细胞的细胞溶解活性、持久持久性、活化和肿瘤浸润的创新策略是推进NK细胞癌症免疫治疗所必需的。随着临床应用的纳米技术和纳米医学的成熟，有更大的机会增加NK细胞治疗癌症的疗效。纳米颗粒的活性分子/细胞因子递送、成像和物理化学性质很好地装备以克服NK细胞癌症免疫疗法的挑战。在这里，我们讨论了NK细胞癌症免疫治疗的最新临床试验，NK细胞癌症免疫治疗的挑战，以及纳米颗粒介导的NK细胞治疗功效增强的进展。
Among various immunotherapies, natural killer (NK) cell cancer immunotherapy using adoptive transfer of NK cells takes a unique position by targeting tumor cells that evade the host immune surveillance. As the first-line innate effector cell, it has been revealed that NK cells have distinct mechanisms to both eliminate cancer cells directly and amplify the anticancer immune system. Over the last 40 years, NK cell cancer immunotherapy has shown encouraging reports in pre-clinic and clinic settings. In total, 288 clinical trials are investigating various NK cell immunotherapies to treat hematologic and solid malignancies in 2021. However, the clinical outcomes are unsatisfying, with remained challenges. The major limitation is attributed to the immune-suppressive tumor microenvironment (TME), low activity of NK cells, inadequate homing of NK cells, and limited contact frequency of NK cells with tumor cells. Innovative strategies to promote the cytolytic activity, durable persistence, activation, and tumor-infiltration of NK cells are required to advance NK cell cancer immunotherapy. As maturing nanotechnology and nanomedicine for clinical applications, there is a greater opportunity to augment NK cell therapeutic efficacy for the treatment of cancers. Active molecules/cytokine delivery, imaging, and physicochemical properties of nanoparticles are well equipped to overcome the challenges of NK cell cancer immunotherapy. Here, we discuss recent clinical trials of NK cell cancer immunotherapy, NK cell cancer immunotherapy challenges, and advances of nanoparticle-mediated NK cell therapeutic efficacy augmentation.
登录
查看更多内容
PD-1和PD-L1检查点信号传导抑制癌症免疫疗法：机制，组合和临床结果。
影响因子：
5.6
作者：
Alsaab HO;Sau S;Alzhrani R;Tatiparti K;Bhise K;Kashaw SK;Iyer AK
通讯作者：
Iyer AK
DOI：
10.1038/s41577-019-0269-6
发表时间：
2020-05
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Irvine DJ;Dane EL
通讯作者：
Dane EL
影响因子：
20.3
作者：
Fauriat, Cyril;Long, Eric O.;Bryceson, Yenan T.
通讯作者：
Bryceson, Yenan T.
影响因子：
15.9
作者：
Alkins, Ryan;Burgess, Alison;Hynynen, Kullervo
通讯作者：
Hynynen, Kullervo
影响因子：
17.1
作者：
Choi, Bongseo;Choi, Hyunjun;Kim, Dong-Hyun
通讯作者：
Kim, Dong-Hyun